Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
A phase 3 trial of Isatuximab, Lenalidomide and Dexamethasone in multiple myeloma, run by Sanofi, active and no longer recruiting.
Overview
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma is a phase 3 interventional study registered as NCT04270409 by Sanofi, with 337 participants enrolled, started 2020-06-16 and due to reach its primary completion in 2030-10-14. Interventions recorded: Isatuximab SAR650984, Lenalidomide, Dexamethasone, Montelukast or equivalent, Acetaminophen and Diphenhydramine or equivalent.
Similar pages
not linked directly; found by shared links- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Dexamethasone, Multiple myeloma and the tag pipeline.
- TrialA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
Shares Sanofi and the tag pipeline.
- TrialA Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory
Shares Isatuximab, Sanofi, Dexamethasone, Multiple myeloma.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialStudy of ODX (OsteoDex) in Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TrialA Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag pipeline.
- TreatmentElenestinib
Shares Sanofi and the tag pipeline.